|
In vitro susceptibility of oral isolates to fluconazole and itraconazole as related to previous antifungal therapy |
|||||||
| Antifungal |
Previous antifungal (n = 176a) |
No previous antifungal (n = 128b) |
P-value |
||||
| S |
SDD |
R |
S |
SDD |
R |
||
|
|
|||||||
| Fluconazole |
149 (84.7) |
17 (9.7) |
10 (5.7) |
112 (93.3) |
3 (2.5) |
5 (4.2) |
0.037 |
| Itraconazole |
133 (75.6) |
22 (12.5) |
21 (11.9) |
112 (93.3) |
4 (3.3) |
4 (3.3) |
0.002 |
|
Data are expressed as number of isolates (percentage). S – Susceptible, SDD – Susceptible dose dependent, R – resistant. Interpretive breakpoint criteria of the CLSI (2002): Fluconazole; S (MIC ≤ 8 μg/ml), SDD (MIC 16 – 32 μg/ml), R (MIC 64 μg/ml) and Itraconazole; S (MIC ≤ 0.125 μg/ml), SDD (MIC 0.25 – 0.5 μg/ml), R (MIC ≥ 1). aC. albicans (143), C. glabrata (19), C. tropicalis (4), S. cerevisiae (2), C. pintolopesii (1). bC. albicans (107), C. glabrata (1), C. tropicalis (4), C. kefyr (3), S. cerevisiae (1), C. dubliniensis (1). | |||||||
Hamza et al. BMC Microbiology 2008 8:135 doi:10.1186/1471-2180-8-135 |
|||||||